drugset
drugset / Trial / NCT04909502

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis

NCT04909502 ↗

Phase 2 Suspended 50 enrolled Emerald Health Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with Relapsing Forms of Multiple Sclerosis (RMS).

Timeline

Start
2021-10-19
Primary completion
2023-12
Completion
2024-04

Outcome

Outcome not reported

Stopped (Enrollment): “Temporary recruitment pause to re-assess the protocol design, specifically the eligibility criteria”

Drugs

EvaluationDrugModalityDoseRoute
Subject ETRINABDIONE Small molecule 50 mg —

Indications

multiple sclerosis